Related Experiment Video
Updated: Nov 20, 2025
09:47
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
2.9K
Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy.
Qi Liu1, Bayonle Aminu1, Olivia Roscow1
1Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Rd E, Guelph, ON N1G2W1, Canada.
International Journal of Molecular Sciences
|January 20, 2021
Summary
This review explores how ubiquitination regulates tumor microenvironments. We highlight E3 ligases and deubiquitinases as key targets for novel cancer therapies and discuss emerging technologies for targeting the tumor microenvironment.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Tumor microenvironments (TMEs) comprise diverse cellular and non-cellular components that promote tumor progression.
- Ubiquitination, a crucial protein modification, governs numerous biological processes.
- Understanding TME regulation via ubiquitination is vital for cancer therapy.
Purpose of the Study:
- To review the role of ubiquitination in regulating the tumor microenvironment.
- To identify E3 ligases and deubiquitinases as potential therapeutic targets.
- To explore emerging technologies for targeting the TME.
Main Methods:
- Literature review focusing on ubiquitination pathways in TME.
- Analysis of the roles of E3 ligases and deubiquitinases.
- Discussion of novel therapeutic strategies and technologies.
Main Results:
- E3 ligases and deubiquitinases significantly modulate both cellular and non-cellular TME components.
- These enzymes represent promising targets for cancer treatment.
- Emerging technologies offer new avenues for TME-targeted therapies.
Conclusions:
- Ubiquitination plays a critical role in shaping the tumor microenvironment.
- Targeting ubiquitination pathways, specifically E3 ligases and deubiquitinases, holds therapeutic potential.
- Advancements in technology are paving the way for innovative TME-targeted cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
03:03mTOR Signaling and Cancer Progression
4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.1K
02:17The Tumor Microenvironment
7.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.3K
01:15Receptor Downregulation in MVBs
2.5K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.5K
01:19Interactions Between Signaling Pathways
6.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
01:27Tumor Immunotherapy
866
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
866